Scpharmaceuticals Inc (NASDAQ:SCPH) – Svb Leerink increased their FY2019 earnings per share (EPS) estimates for Scpharmaceuticals in a research report issued to clients and investors on Wednesday, November 13th. Svb Leerink analyst A. Fadia now expects that the company will earn ($1.72) per share for the year, up from their previous forecast of ($1.88). Svb Leerink also issued estimates for Scpharmaceuticals’ Q4 2019 earnings at ($0.53) EPS.
Other equities analysts also recently issued reports about the stock. HC Wainwright initiated coverage on shares of Scpharmaceuticals in a report on Tuesday, October 15th. They set a “buy” rating and a $13.00 target price on the stock. Zacks Investment Research downgraded shares of Scpharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, October 9th. Finally, ValuEngine upgraded shares of Scpharmaceuticals from a “hold” rating to a “buy” rating in a report on Thursday. Three equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. Scpharmaceuticals presently has a consensus rating of “Hold” and an average price target of $8.00.
Scpharmaceuticals (NASDAQ:SCPH) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.33) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.45) by $0.12.
A number of institutional investors and hedge funds have recently modified their holdings of SCPH. Alambic Investment Management L.P. acquired a new position in Scpharmaceuticals during the second quarter worth $191,000. Eversept Partners LP acquired a new position in Scpharmaceuticals during the second quarter worth $556,000. Jacobs Levy Equity Management Inc. increased its holdings in Scpharmaceuticals by 55.8% during the second quarter. Jacobs Levy Equity Management Inc. now owns 36,921 shares of the company’s stock worth $118,000 after buying an additional 13,225 shares during the last quarter. Paloma Partners Management Co acquired a new position in Scpharmaceuticals during the second quarter worth $96,000. Finally, Morgan Stanley increased its holdings in shares of Scpharmaceuticals by 32.0% in the second quarter. Morgan Stanley now owns 13,633 shares of the company’s stock valued at $43,000 after purchasing an additional 3,306 shares during the last quarter. Institutional investors and hedge funds own 39.66% of the company’s stock.
Scpharmaceuticals Company Profile
scPharmaceuticals Inc, a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. The company's lead product candidate is Furoscix that consists of proprietary subcutaneous formulation of furosemide, which is delivered through the SmartDose drug delivery system for treatment of congestion in decompensated heart failure patients outside of the acute care setting.
Featured Article: How Investors Can Profit from Options Trading
Receive News & Ratings for Scpharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scpharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.